Author:
Mbatchi Litaty C.,Gassiot Matthieu,Pourquier Philippe,Goberna Alejando,Mahammedi Hakim,Mourey Loic,Joly Florence,Lumbroso Serge,Evrard Alexandre,Houede Nadine
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference20 articles.
1. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32(8):760–767. doi:
10.1200/JCO.2013.50.3961
2. Huang S, Bjornsti MA, Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2(3):222–232
3. Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563–585. doi:
10.1097/FPC.0b013e328364db84
4. Cai P, Tsao R, Ruppen ME (2007) In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35(9):1554–1563. doi:
10.1124/dmd.107.014746
5. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U (1998) Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285(3):1104–1112
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献